- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05240300
A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis
February 4, 2022 updated by: BiomX, Inc.
A Phase 1b/2a, Double-blind (Sponsor Open), Randomized, Vehicle-controlled Study of Topically Administered BX005-A in Subjects With Moderate to Severe Atopic Dermatitis
The purpose of study BMX-05-001 is to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically in adult subjects with moderate to severe atopic dermatitis (AD).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
BMX-05-001 is a double-blind (Sponsor open), randomized, vehicle-controlled, first-in-human, Phase 1b/2a study to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically twice daily for 8 weeks to lesional areas in adult subjects with moderate to severe atopic dermatitis (AD).
Study Type
Interventional
Enrollment (Anticipated)
48
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Urania Rappo, MD
- Phone Number: 203-364-2364
- Email: uraniar@biomx.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female ≥ 18 years old
- Confirmed clinical diagnosis of active AD with at least a 6-month history and clinically stable AD for ≥ 1 month
- Clinical diagnosis of moderate or severe AD with a vIGA-AD score of ≥ 3 and a lesion vIGA-AD score ≥ 3 in the target AD skin lesion
- BSA with AD of 2%-30%, excluding scalp
- Colonized with S. aureus in at least one AD skin lesion
- Female subjects of non-childbearing potential must meet at least 1 of the following: postmenopausal status; documented hysterectomy and/or bilateral oophorectomy; or medically confirmed ovarian failure. All other female subjects (including those who have undergone tubal ligation) are of childbearing potential.
- Female subjects of childbearing potential who have a negative urine pregnancy test
- Effective contraceptive method for female subjects of childbearing potential and for male subjects
- Able to understand study procedures and attend all study visits
- Willing to refrain from use of all other systemic or topical agents for the treatment of AD or the prevention of complications of AD (e.g., secondary infection)
Exclusion Criteria:
- Active skin infection and/or systemic infection requiring systemic or topical antimicrobial agents and/or a skin drainage procedure, or a history of recurrent bacterial skin infections
- Other concurrent skin diseases which could interfere with the diagnosis and/or management of AD (e.g., psoriasis, contact dermatitis), or presence of open, chronic non-healing wounds in their treatable AD lesions
- Known hypersensitivity to study drug, its excipients, simethicone, and/or any emollient to be used in study
Planned treatment with a prohibited medication during study, or received a prohibited medication within time frame noted below, prior to first dose of study drug:
Must be discontinued at least 28 Days prior to Day 1:
- Systemic corticosteroids
- Systemic JAK inhibitors and immunosuppressive agents
- Nonbiologic investigational agent or device
- Total body phototherapy
Must be discontinued at least 14 Days prior to Day 1:
- Systemic antimicrobials
- Probiotics and prebiotics
- Prescription skin barrier repair products
Must be discontinued at least 7 Days prior to Day 1:
- Topical therapies for AD
- Topical antimicrobials and antiseptic cleansers
- Use of antibacterial soaps or topical sodium hypochlorite-based products
- Current emollient use (need to convert to study emollient 7 days prior to Day 1)
- Currently being treated with biologic agents; exception: may be enrolled if dupilumab was discontinued at least 12 weeks prior to Day 1, or if other biologics were discontinued at least 5 half-lives prior to Day 1.
- Female subjects who are pregnant, breastfeeding, or planning a pregnancy, or are of childbearing potential and not using an effective and allowed form of contraception.
- Enrolled in another investigational study 30 days prior to Screening or 90 days prior to Screening if investigational agent was a phage product.
- Other medical and/or psychiatric conditions which makes the subject inappropriate for study participation, increases likelihood that the subject will not be able to comply with study therapy or procedures and/or which places the subject at undue risk
- Active abuse of alcohol and/or illicit drugs or a history of such abuse that would make it difficult for the subject to comply with study and/or place subject at undue risk
- Known infection with human immunodeficiency virus (HIV) or other immunodeficiency disorder.
- Current or prior history of a malignant neoplasm other than previously treated non-melanoma skin cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BX005-A
twice daily topical application x 8 weeks
|
phage gel
|
Placebo Comparator: Vehicle
twice daily topical application x 8 weeks
|
vehicle gel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability: adverse events (AEs)
Time Frame: Through study completion Day 225 (+7 days)
|
The proportion of subjects with any AE, treatment-emergent AE (TEAE), serious adverse event, TEAE leading to study drug discontinuation, TEAE leading to study discontinuation, or death
|
Through study completion Day 225 (+7 days)
|
Safety and tolerability: laboratory abnormalities
Time Frame: Through study completion Day 225 (+7 days)
|
The proportion of subjects with abnormalities in laboratory parameters, graded according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
|
Through study completion Day 225 (+7 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in log S. aureus density, measured by colony forming units (CFU)/cm2 in the target AD skin lesion in BX005-A vs vehicle groups
Time Frame: Day 1 through Day 71 (± 2 days)
|
S. aureus CFU in target AD skin lesion
|
Day 1 through Day 71 (± 2 days)
|
Change from baseline in log S. aureus density, measured by quantitative PCR (qPCR)/cm2 in the target AD skin lesion in BX005-A vs vehicle groups
Time Frame: Day 1 through Day 71 (± 2 days)
|
S. aureus qPCR in target AD skin lesion
|
Day 1 through Day 71 (± 2 days)
|
% change from baseline in the Eczema Area and Severity Index (EASI) score in BX005-A vs vehicle groups
Time Frame: Day 1 through Day 71 (± 2 days)
|
Eczema Area and Severity Index of all lesional skin areas (range 0-72); higher score indicates worse atopic dermatitis
|
Day 1 through Day 71 (± 2 days)
|
Proportion of subjects who achieve a Validated Investigator Global Assessment AD (vIGA-AD) score of 0 or 1 with at least a 2-grade reduction from baseline in BX005-A vs vehicle groups
Time Frame: Day 1 through Day 71 (± 2 days)
|
vIGA-AD
|
Day 1 through Day 71 (± 2 days)
|
Change from baseline in SCORing Atopic Dermatitis (SCORAD) index in BX005-A vs vehicle groups
Time Frame: Day 1 through Day 71 (± 2 days)
|
SCORing Atopic Dermatitis index of all lesional skin areas (range 0-103); higher score indicates worse atopic dermatitis
|
Day 1 through Day 71 (± 2 days)
|
Change from baseline in SCORing Atopic Dermatitis (SCORAD) index of the target AD skin lesion in BX005-A vs vehicle groups
Time Frame: Day 1 through Day 71 (± 2 days)
|
Local SCORing Atopic Dermatitis index (range 0-15); higher score indicates worse atopic dermatitis
|
Day 1 through Day 71 (± 2 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Urania Rappo, MD, BiomX, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 1, 2022
Primary Completion (Anticipated)
June 1, 2023
Study Completion (Anticipated)
June 1, 2023
Study Registration Dates
First Submitted
January 23, 2022
First Submitted That Met QC Criteria
February 4, 2022
First Posted (Actual)
February 15, 2022
Study Record Updates
Last Update Posted (Actual)
February 15, 2022
Last Update Submitted That Met QC Criteria
February 4, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BMX-05-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
Regeneron PharmaceuticalsSanofiRecruitingModerate-to-Severe Atopic Dermatitis | Atopic EczemaUnited States
-
AnaptysBio, Inc.RecruitingAtopic Dermatitis EczemaUnited States, Canada, Georgia, New Zealand
Clinical Trials on BX005-A
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedCorneal Infiltrative Events | Corneal InflammationUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Coopervision, Inc.Completed
-
Bausch & Lomb IncorporatedCompleted
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.University of ManchesterCompleted
-
University of OttawaCompletedBorderline Personality Disorder | Deliberate Self Harm